[Ip-health] Infojustice Roundup - February 16, 2015

Michael Palmedo mpalmedo at wcl.american.edu
Mon Feb 16 11:50:41 PST 2015

Infojustice Roundup




UNITAID: Hepatitis C Medicines - Technology and Market Landscape


[Mike Isbell, Renée Ridzon, and Karin Timmermans] Executive Summary: Hepatitis C virus (HCV) is a major global health problem. With 80−150 million people worldwide chronically infected with the virus, the prevalence of HCV is higher than that of the human immunodeficiency virus (HIV)... Widespread scale-up of DAAs [direct-acting antivirals] in low- and middle-income countries is not currently feasible due to their very high prices... The high prices of DAAs are not related to the cost of production. Assuming sufficient volumes, a recent academic analysis estimated that minimum production costs for a 12-week treatment course of several leading DAA combinations range from US$ 118 to US$193 per person. Patents pose a barrier to affordability and scale-up, although voluntary licences offer an avenue for generic production. Click here for more. <http://infojustice.org/archives/33925> 


Intellectual Property Provisions in the Leaked Japanese RCEP Proposal that Threaten the Availability of Generic Medicines


[Mike Palmedo] Last week, the 16 Asian and Pacific countries negotiating the Regional Comprehensive Economic Partnership (RCEP) are meeting in Thailand.  This trade agreement will include Australia, Brunei, Cambodia, China, India, Indonesia, Laos, Malaysia, Myanmar, New Zealand, Japan, the Philippines, Singapore, South Korea, Thailand, and Vietnam. According to the RCEP’s Guiding Principles stated at the beginning of the negotiations in 2012, the agreement will include an intellectual property chapter to promote “cooperation in the utilization, protection and enforcement” of IPR. Click here for more. <http://infojustice.org/archives/33910> 


Médecins du Monde is filing a patent challenge to Gilead’s patent on sofosbuvir at the European Patent Office


[Médecins du Monde] Doctors of the World – Médecins du Monde (MDM) has filed a European patent challenge against the Hepatitis C virus (HCV) drug, sofosbuvir. In recent months, Médecins du Monde and its partners have raised the alarm around the problems caused by the cost of new treatments against hepatitis C and of sofosbuvir [2] in particular. The U.S.-based pharmaceutical company Gilead holds a monopoly for sofosbuvir and is marketing a 12-week course treatment at extremely high prices – 41 000 euros in France and 44 000 euros in the United Kingdom – thereby hindering access to the drug for People Living with HCV. Click here for more. <http://infojustice.org/archives/33905> 




More information about the Ip-health mailing list